PTGES3 Identified as Key Regulator of Androgen Receptor in Prostate Cancer
Genome-scale CRISPR screens identified PTGES3 as a key regulator of androgen receptor (AR) stability and activity in advanced prostate cancer, revealing its potential as a therapeutic target to overcome resistance to AR-targeted therapies in castration-resistant prostate cancer (CRPC).